Actuate Therapeutics Investor Event at ASCO to Discuss Elraglusib Phase 2 Topline Data in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
| DATE: | May 31, 2025 |
|---|---|
| TIME: | 6:30 PM CDT |
| LOCATION: | Marriott Marquis Chicago, 2121 S Prairie Ave, Chicago, IL 60616 |
About The Event
Join Actuate Therapeutics for an in-person and virtual investor event to review topline data from the Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line treatment of mPDAC. These results will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
The event will feature a fireside discussion moderated by Daniel Schmitt, President & CEO of Actuate and key opinion leaders (KOLS):
- Tanios Bekaii-Saab, MD – Mayo Clinic College of Medicine and Science
- Deva Mahalingam, MD, PhD – Northwestern University Feinberg School of Medicine
- Rachna Shroff, MD, MS, FASCO – University of Arizona
- Colin D. Weekes, MD, PhD – Massachusetts General Hospital Cancer Center, Harvard Medical School
Key topics will include an overview of the current treatment landscape for mPDAC, the therapeutic potential of elraglusib, and a detailed review of the topline data.
A live question and answer session will follow the formal discussion.